scholarly journals Memantine: A New Mood Stabilizer for Treatment-Resistant Bipolar Disorders

10.5772/32196 ◽  
2012 ◽  
Author(s):  
Gino Serra ◽  
Giulia Serra ◽  
Alexia E. ◽  
Francesca Demontis ◽  
Athanasio Koukopoulos
Keyword(s):  
Bipolar Disorders ◽  
Mood Stabilizer ◽  
Treatment Resistant

scholarly journals Prophylaxis Latency and Outcome in Bipolar Disorders

2003 ◽  
Vol 48 (7) ◽  
pp. 449-457 ◽  
Author(s):  
Christopher Baethge ◽  
Leonardo Tondo ◽  
Irene M Bratti ◽  
Tom Bschor ◽  
Michael Bauer ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Treatment Response ◽  
Prophylactic Treatment ◽  
Bipolar Disorders ◽  
Mood Stabilizer ◽  
Adult Patients ◽  
Apparent Reduction

Objective: To analyze new and reviewed findings to evaluate relations between treatment response and latency from onset of bipolar disorder (BD) to the start of mood-stabilizer prophylaxis. Method: We analyzed our own new data and added findings from research reports identified by computerized searching. Results: We found 11 relevant studies, involving 1485 adult patients diagnosed primarily with BD. Reported latency to prophylaxis averaged 9.6 years (SD 1.3), and follow-up in treatment averaged 5.4 years (SD 3.1). Greater illness intensity and shorter treatment latency were closely associated, resulting in a greater apparent reduction in morbidity with earlier treatment. However, this finding was not sustained after correction for pretreatment morbidity, and treatment latency did not predict morbidity during treatment. Therefore, assessments based on improvement with treatment, or without correction for pretreatment morbidity, can be misleading. Conclusions: Available evidence does not support the proposal that delayed prophylaxis may limit response to prophylactic treatment in BD and related disorders.

In Vitro Effect Of VPA Together With ATRA and Ara-C On Proliferation and Viability Of Pediatric AML Cell Line THP-1

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4924-4924
Author(s):  
Sema Anak ◽  
Ayca Gul Kanbay ◽  
Cagri Gulec
Keyword(s):  
Cell Line ◽  
Animal Studies ◽  
Conflicts Of Interest ◽  
Bipolar Disorders ◽  
Mood Stabilizer ◽  
Leukemic Cells ◽  
Pcr Method ◽  
Pediatric Aml ◽  
Vitro Effect

Abstract In addition to its HDAC inhibitory property, Valproic acid is also known as anticonvulsant agent and mood stabilizer in the treatment of bipolar disorders. Due to its HDAC inhibitory activity and its safety in long-term usage, VPA is presumed to be a good candidate for cancer treatment. It is known that VPA induces apoptosis in leukemic cells, while not in normal cells. VPA is reported as an effective agent in treatment of pediatric AML in clinical studies and  is also well tolerated in children. In this study, the in vitro effect of the combination of HDAC inhibitor VPA with Ara-C and ATRA which are used in AML therapy, is investigated on AML cells. For this purpose, the effect of VPA, Ara-C and ATRA on proliferation of AML cell line THP-1 is tested in cell culture condition. To assess the effect on cell proliferation, p21 expression was measured by RT-PCR method. The use of VPA alone, did not affect the cell viability, while increasing the expression of the p21 gene. VPA in combination with Ara-C, increased the expression of p21 gene more than the other combinations. Thus it is determined that the p21 gene expression is higher as a result of known cell cycle stops. In this study, the understanding of how effective is VPA together with ATRA and/or Ara-C on AML cells, might be a good start for animal studies and clinical trials as a remarkable data for the development of new chemotherapeutic protocols. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Mobile Phone and Wearable Sensor-Based mHealth Approaches for Psychiatric Disorders and Symptoms: Systematic Review

2019 ◽  
Vol 6 (2) ◽  
pp. e9819 ◽  
Author(s):  
Jussi Seppälä ◽  
Ilaria De Vita ◽  
Timo Jämsä ◽  
Jouko Miettunen ◽  
Matti Isohanni ◽  
...  
Keyword(s):  
Systematic Review ◽  
Psychiatric Disorders ◽  
Wearable Sensors ◽  
Bipolar Disorders ◽  
Quantitative Information ◽  
Sensor Data ◽  
Depression Symptoms ◽  
Cochrane Central Register ◽  
Treatment Resistant ◽  
Horizon 2020

BackgroundMobile Therapeutic Attention for Patients with Treatment-Resistant Schizophrenia (m-RESIST) is an EU Horizon 2020-funded project aimed at designing and validating an innovative therapeutic program for treatment-resistant schizophrenia. The program exploits information from mobile phones and wearable sensors for behavioral tracking to support intervention administration.ObjectiveTo systematically review original studies on sensor-based mHealth apps aimed at uncovering associations between sensor data and symptoms of psychiatric disorders in order to support the m-RESIST approach to assess effectiveness of behavioral monitoring in therapy.MethodsA systematic review of the English-language literature, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, was performed through Scopus, PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials databases. Studies published between September 1, 2009, and September 30, 2018, were selected. Boolean search operators with an iterative combination of search terms were applied.ResultsStudies reporting quantitative information on data collected from mobile use and/or wearable sensors, and where that information was associated with clinical outcomes, were included. A total of 35 studies were identified; most of them investigated bipolar disorders, depression, depression symptoms, stress, and symptoms of stress, while only a few studies addressed persons with schizophrenia. The data from sensors were associated with symptoms of schizophrenia, bipolar disorders, and depression.ConclusionsAlthough the data from sensors demonstrated an association with the symptoms of schizophrenia, bipolar disorders, and depression, their usability in clinical settings to support therapeutic intervention is not yet fully assessed and needs to be scrutinized more thoroughly.

Korean medication algorithm for bipolar disorder (KMAP-BP): Changes in treatment strategies for bipolar depression over 12 years

2017 ◽  
Vol 41 (S1) ◽  
pp. S423-S423
Author(s):  
D.I. Jon ◽  
J.S. Seo ◽  
W. Kim ◽  
J.G. Lee ◽  
Y.C. Shin ◽  
...  
Keyword(s):  
Bipolar Depression ◽  
Treatment Options ◽  
Treatment Strategies ◽  
Severe Depression ◽  
Bipolar Disorders ◽  
Mood Stabilizer ◽  
First Line ◽  
Moderate Depression ◽  
Competing Interest ◽  
Nonpsychotic Depression

IntroductionMany guidelines for bipolar disorders have been introduced based on evidences. In contrast, KMAP-BP was developed by an expert-consensus.ObjectiveTo summarize the medication strategies for bipolar depression over four published KMAP-BP (2002, 2006, 2010, and 2014).MethodsThe questionnaire using a nine-point scale had covered some clinical situations with many treatment options about the appropriateness of treatment.ResultsFor mild-to-moderate depression, antidepressant (AD) + mood stabilizer (MS) in early editions and MS or lamotrigine monotherapy and AAP + (MS or lamotrigine) in later editions were preferred strategies. For severe nonpsychotic depression, MS + AD was the only first-line medication in early editions. In 2014, various medications [MS + AAP (atypical antipsychotic), AAP + lamotrigine, MS + AD] were preferred. Valproate and lithium has been rated as first-line MS in all editions. Lamotrigine were positively preferred later. Adjunctive AD was accepted as first-line strategy for severe depression in all editions. Preference of AAP also has been increased remarkably. Adjunctive AAP was not first-line treatment for mild-to-moderate depression in all editions, but was for nonpsychotic depression in 2010 and 2014 and for psychotic depression in all editions. Recommended AAPs have been changed over 12 years: olanzapine and risperidone in 2002 and quetiapine, aripiprazole, and olanzapine in 2014 were first-line AAP.ConclusionThere have been evident preference changes: increased for AAP and lamotrigine and decreased for AD. The high preferences for aripiprazole and lamotrigine in later editions were likely derived from favorable tolerability.Disclosure of interestThe authors have not supplied their declaration of competing interest.

The Use of Topiramate in Mood Stabilization

2002 ◽  
Vol 36 (7-8) ◽  
pp. 1277-1281 ◽  
Author(s):  
Ian D Maidment
Keyword(s):  
Bipolar Disorder ◽  
Bipolar Disorders ◽  
Mood Stabilizer ◽  
Mood Stabilizers ◽  
Double Blind ◽  
Data Synthesis ◽  
Complex Disorder ◽  
Search Terms ◽  
Clinical Literature ◽  
Mood Stabilization

OBJECTIVE: To review data on the effectiveness of topiramate as a mood stabilizer. DATA SOURCES: Clinical literature accessed through MEDLINE (1985–September 2001) and the manufacturer. Key search terms included topiramate, mania, mood stabilizer, and bipolar disorder. DATA SYNTHESIS: The traditional standard therapy for bipolar disorder has been lithium. Other mood stabilizers are increasingly being used to manage this complex disorder. Studies that used topiramate in bipolar disorders were evaluated. CONCLUSIONS: The present data from open trials suggest that topiramate may possibly possess antimanic properties. Controlled, double-blind studies are required to confirm this efficacy.

Reassessing Carbamazepine in Bipolar Disorders

CNS Spectrums ◽  
2005 ◽  
Vol 10 (S1) ◽  
pp. 6-11 ◽  
Author(s):  
Terence A. Ketter
Keyword(s):  
Bipolar Disorder ◽  
Maintenance Treatment ◽  
Atypical Antipsychotics ◽  
Bipolar Depression ◽  
Bipolar Disorders ◽  
Clinical Implications ◽  
Treatment Resistant ◽  
Historical Trends ◽  
Conventional Antipsychotics ◽  
Important Progress

This discussion focuses on the historical trends of carbamazepine in the treatment of acute mania, acute bipolar depression, and as maintenance treatment for bipolar disorder. Clinical implications of efficacy, safety, tolerability, and drug interactions associated with carbamazepine are discussed as well.Important progress in bipolar disorders therapeutics began in the 1970s with lithium and the conventional antipsychotics, and continued in the 1980s with carbamazepine, in the 1990s with divalproex, and in the 2000s with lamotrigine and the introduction of the atypical antipsychotics. Electroconvulsive therapy (ECT) has been used throughout these periods and still has a place in bipolar disorder, especially for severe, treatment-resistant, and very acute cases.

Bipolar Disorder and Outcomes of Monotherapy with Lithium, Valproate, Quetiapine, Olanzapine, Venlafaxine, and Citalopram

2021 ◽  
Author(s):  
Jens Bohlken ◽  
Steffi Riedel-Heller ◽  
Michael Bauer ◽  
Karel Kostev
Keyword(s):  
Bipolar Disorder ◽  
Retrospective Study ◽  
Treatment Failure ◽  
Maintenance Treatment ◽  
Bipolar Disorders ◽  
Mood Stabilizer ◽  
Hazard Ratio ◽  
Bipolar Patients

Abstract Introduction The aim of this study was to compare the outcomes of monotherapy in individuals with bipolar disorder who are prescribed lithium, valproate, quetiapine, olanzapine, venlafaxine, or citalopram in private psychiatric practices in Germany. Methods This retrospective study included bipolar disorder patients who had initially started on a monotherapy with lithium, valproate, quetiapine, olanzapine, venlafaxine, or citalopram in 93 private neuropsychiatric practices in Germany between January 2006 and December 2017. Treatment failure was defined as time to discontinuation of medication or addition of another mood stabilizer, antipsychotic, antidepressant, or benzodiazepine. Results A total of 4990 bipolar patients was examined for the period between 2006 and 2019. Initially, monotherapy with lithium (n=1.098), valproate (n=502), quetiapine (n=927), olanzapine (n=927), venlafaxine (n=574), or citalopram (n=962) was prescribed. Within 24 months, treatment failure had occurred in 76.3% (lithium), 85.1% (valproate), 84.6% (quetiapine), 85.2% (venlafaxine), 92.1% (olanzapine), and 86.6% (citalopram) of patients, respectively. The hazard ratio for treatment failure compared to lithium as reference was highest for olanzapine at 1.66 (1.46–1.88), followed by citalopram 1.27 (1.15–1.39), quetiapine 1.18 (1.07–1.29), valproate 1.18 (1.06–1.33), and venlafaxine 1.14 (1.02–1.27). Conclusions Our results underline the importance of lithium in the maintenance treatment of bipolar disorders.

scholarly journals Mobile Phone and Wearable Sensor-Based mHealth Approaches for Psychiatric Disorders and Symptoms: Systematic Review (Preprint)

2018 ◽  
Author(s):  
Jussi Seppälä ◽  
Ilaria De Vita ◽  
Timo Jämsä ◽  
Jouko Miettunen ◽  
Matti Isohanni ◽  
...  
Keyword(s):  
Systematic Review ◽  
Psychiatric Disorders ◽  
Wearable Sensors ◽  
Bipolar Disorders ◽  
Quantitative Information ◽  
Sensor Data ◽  
Depression Symptoms ◽  
Cochrane Central Register ◽  
Treatment Resistant ◽  
Horizon 2020

BACKGROUND Mobile Therapeutic Attention for Patients with Treatment-Resistant Schizophrenia (m-RESIST) is an EU Horizon 2020-funded project aimed at designing and validating an innovative therapeutic program for treatment-resistant schizophrenia. The program exploits information from mobile phones and wearable sensors for behavioral tracking to support intervention administration. OBJECTIVE To systematically review original studies on sensor-based mHealth apps aimed at uncovering associations between sensor data and symptoms of psychiatric disorders in order to support the m-RESIST approach to assess effectiveness of behavioral monitoring in therapy. METHODS A systematic review of the English-language literature, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, was performed through Scopus, PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials databases. Studies published between September 1, 2009, and September 30, 2018, were selected. Boolean search operators with an iterative combination of search terms were applied. RESULTS Studies reporting quantitative information on data collected from mobile use and/or wearable sensors, and where that information was associated with clinical outcomes, were included. A total of 35 studies were identified; most of them investigated bipolar disorders, depression, depression symptoms, stress, and symptoms of stress, while only a few studies addressed persons with schizophrenia. The data from sensors were associated with symptoms of schizophrenia, bipolar disorders, and depression. CONCLUSIONS Although the data from sensors demonstrated an association with the symptoms of schizophrenia, bipolar disorders, and depression, their usability in clinical settings to support therapeutic intervention is not yet fully assessed and needs to be scrutinized more thoroughly.

Sign in / Sign up

Export Citation Format

Share Document